OR-RADISYS
21.2.2024 14:01:28 CET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today announced the launch of its groundbreaking 5G Advanced Wireless Connectivity Software designed specifically for Industry 4.0 and private 5G networks. This significant advancement in the evolution of enterprise solutions offers unparalleled capabilities to establish private networks with enhanced performance, ease of deployability and management, and data protection with guaranteed Quality of Service (QoS). Radisys’ innovative 5G Advanced Wireless Connectivity software enables enterprises to meet the surging demand for private 5G and Industry 4.0 solutions capable of meeting evolving business needs.
By seamlessly integrating licensed, lightly licensed (CBRS) and unlicensed Wifi access via N3IWF, the advanced software solution delivers low latency, cloud-native solutions for both the RAN and Core networks. The cloudification of both RAN and Core networks offers flexible deployment options that allow for segregated and collocated distribution units (DU), central units (CU) and user plane functions (UPF) within a Kubernetes cloud environment, with the additional capability of deploying CU and UPF in the public cloud. This streamlined approach facilitates automation and simplifies the deployment of 5G networks, ultimately reducing capital expenditure (CapEx) and operational expenditure (OpEx) for private and Industry 4.0 5G operators.
Key features include:
- Time Sensitive Network (TSN) and 5G Ultra-Reliable Low Latency Communication (5G-URLLC) features for deterministic, low latency communication, targeted at Industry 4.0 automation requirements.
- 5G Reduced Capability (RedCap) for connectivity of the low-cost sensors enabling smart manufacturing processes and more.
- N3IWF (Non-3GPP Inter-working Function) to allow convergence of existing Wifi access with the 5G Core Network in enterprise and manufacturing sectors. Additionally, N3IWF enables integration of non-3GPP traditional and legacy access technologies with the 5G. This enhances accessibility and flexibility, providing a high-performance network solution for Industry 4.0 private and enterprise networks with reduced CapEx.
- CBRS band support with ease of integration into CBRS networks via a scalable CBRS Domain Proxy to enable acceleration of CBRS deployment for private and enterprise networks.
- Enabling intelligent Private 5G and Industry 4.0 solutions through advanced RAN functions controlled via ORAN E2 interface and pre-integrated with xApps/rApps and RIC platforms from different vendors.
“Recognizing the specific needs of Industry 4.0 and private 5G networks, Radisys continues to deliver innovative advanced 5G RAN and Core features to accelerate the adoption of 5G in these markets,” said Munish Chhabra, Head of Mobility Software and Services Business, Radisys. “Radisys remains committed to driving innovation in wireless technologies, empowering businesses to harness the full potential of Industry 4.0 and the future of connectivity for private and enterprise networks through its award-winning Connect RAN 5G Software solution.”
Meet with Radisys at MWC Barcelona
Experience Radisys’ disaggregated Connect RAN solutions, including demonstrations of its 5G Advanced Wireless Connectivity RAN software, at MWC Barcelona, Stand 2D50. To schedule a meeting with Radisys’ RAN experts, contact open@radisys.com.
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221279407/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom